The global cardiac tissue engineering market, valued at US$546.8 million in 2023, is forecasted to grow at a robust CAGR of 16.5%, reaching US$621.2 million in 2024 and an impressive US$1,333.6 million by 2029. This growth is driven by increased demand for regenerative medicine, advancements in 3D bioprinting, and rising cardiovascular disease prevalence. Key drivers include substantial support from market leaders and government bodies, as evidenced by a USD 23.6 million fundraising campaign in Canada aimed at developing innovative heart disease treatments. However, high treatment costs pose a significant restraint, limiting accessibility and adoption. Opportunities for growth lie in the expanding stem cell research, which enhances cardiac tissue engineering’s potential for developing effective therapies. Challenges include limited awareness among patients and healthcare professionals, hindering the integration of these advanced treatments. North America leads the market due to high healthcare spending and investment in medical research. Prominent players include Terumo Corporation, Artivion, Baxter International, and others, with notable recent developments such as REPROCELL’s partnership with Cellco Labs and Artivion’s acquisition of Ascyrus Medical.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264276500
Browse in-depth TOC on “Cardiac Tissue Engineering Market“
426 – Tables54 – Figures336 – Pages
Based on material, the cardiac tissue engineering market is segmented into stem cells, and scaffolds. Among these, in 2023, scaffolds segment accounts for significant position in the cardiac tissue engineering market due to their crucial role in creating vascular grafts, patches, and heart valves. These structures provide a supportive framework that mimics the extracellular matrix, promoting cell attachment, growth, and differentiation. They enable the integration of bioengineered tissues with the body, enhancing the repair and regeneration of damaged cardiac tissue. Advances in scaffold materials, such as biodegradable polymers and 3D bioprinting, have improved their effectiveness and customization. Additionally, the increasing prevalence of cardiovascular diseases drives demand for innovative treatments, further accelerating scaffold development. This rapid growth is fuelled by ongoing research, technological advancements, and the clinical need for effective, biocompatible solutions in cardiac tissue engineering.
The cardiac tissue engineering market is divided into two segments based on the material used: scaffolds and stem cells. Because they are essential to the creation of heart valves, patches, and vascular grafts, the scaffolds section of the cardiac tissue engineering market is expected to have a prominent position in 2023. These structures facilitate cell adhesion, development, and differentiation by offering a scaffolding structure that resembles the extracellular matrix. They make it possible for bioengineered tissues to be integrated with the body, which improves damaged heart tissue regeneration and repair. Technological developments in scaffold materials, like 3D bioprinting and biodegradable polymers, have increased scaffold personalization and effectiveness. Further driving the need for novel treatments is the rising incidence of cardiovascular illnesses, which expedites the creation of scaffolds. This quick expansion is driven by continuing research, technical developments, and the and the clinical need in cardiac tissue engineering for efficient, biocompatible solutions.
Based on application, the cardiac tissue engineering market is segmented into myocardial infarction treatment, heart valve repair/replacement, congenital heart disease treatment, others. Among these, in 2023, heart valve repair/replacement segment is the fastest growing in the cardiac tissue engineering market attributed to the increasing prevalence of aortic and pulmonary stenosis. As the global population ages, the incidence of these valvular diseases is increasing, driving demand for effective treatments. Traditional surgical methods, though effective, come with significant risks and limitations. Advances in cardiac tissue engineering offer innovative alternatives that promise improved outcomes and reduced recovery times. Additionally, the launch of new, biocompatible heart valve products has accelerated, providing a wider array of options tailored to patient-specific needs. These engineered valves not only aim to replicate the natural biomechanics of the heart but also promote tissue regeneration, leading to more durable and functional repairs. The combination of technological advancements & increased clinical need, and favourable regulatory environments has fostered significant investment and research in this sector. Thus, the heart valve repair and replacement market segment are experiencing rapid growth, driven by its potential to transform the treatment landscape for patients with valvular heart diseases.
The cardiac tissue engineering market has been split into segments according to application, comprising treatment for congenital heart disease, myocardial infarction, and heart valve repair/replacement. Due to the rising incidence of aortic and pulmonary stenosis, the cardiac tissue engineering market’s heart valve repair/replacement sector is projected to develop at the quickest rate in 2023. The frequency of these valvular illnesses is rising as the world’s population ages, which is pushing up demand for efficient therapies. Though they’re effective, traditional surgical procedures have a lot of hazards and drawbacks. Cardiac tissue engineering advances present novel options that promise better results and shorter recovery times. Furthermore, a greater range of alternatives catered to the unique demands of each patient are now available due to the acceleration of the availability of new, biocompatible heart valve technologies. In addition to trying to mimic the heart’s natural biomechanics, these engineered valves also encourage tissue regeneration, which could result in more robust and useful repairs. Significant investment and research in this field have been encouraged by a mix of favorable regulatory conditions, rising clinical demand, and technology improvements. As a result, the market segment for heart valve replacement and repair is expanding rapidly due to its potential to change how individuals with valvular heart diseases are treated.
Based on end users, the cardiac tissue engineering market is segmented into hospitals & clinics, Academic & research institutes, and others. Among these, hospitals and clinics holds a notable share in the cardiac tissue engineering market by end-users due to the rising incidence of cardiovascular diseases, which leads to increased hospitalizations. These healthcare settings are the primary locations where advanced cardiac treatments are administered, making them central to patient care. The growing adoption of innovative cardiac tissue engineering techniques and technologies, such as bioengineered grafts and valves, further strengthens their position. Hospitals and clinics are equipped with the necessary infrastructure and skilled professionals to implement these cutting-edge treatments, ensuring optimal patient outcomes. This comprehensive approach to addressing cardiovascular conditions through advanced tissue engineering solutions solidifies their dominance in the market.
The cardiac tissue engineering market is split into hospitals & clinics, academic & research institutes, and others depending on the end users. Due to the increased hospitalizations caused by the rising frequency of cardiovascular disorders, hospitals and clinics occupy a significant part of the end-user cardiac tissue engineering market. These healthcare institutions are essential to patient care since they are the main sites for the delivery of cutting-edge cardiac treatments. Their position is further strengthened by the increasing use of cutting-edge cardiac tissue engineering methods and tools, such as bioengineered valves and grafts. Clinics and hospitals have the facilities and trained professionals needed to apply these state-of-the-art therapies, guaranteeing the best possible results for their patients. Their dominance is further cemented by their all-encompassing approach to treating cardiovascular diseases with cutting-edge tissue engineering treatments.
North America dominates the global cardiac tissue engineering market
The cardiac tissue engineering market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The North American region accounts for the largest share in the cardiac tissue engineering market in 2023, due to significant increases in healthcare expenditure and the high prevalence of cardiovascular diseases. The robust healthcare infrastructure and substantial funding for medical research and development facilitate the adoption and advancement of innovative cardiac treatments. Additionally, the region’s aging population contributes to a higher incidence of cardiovascular conditions, driving demand for advanced therapeutic solutions. North America’s strong focus on technological innovation and early adoption of cutting-edge medical technologies, including cardiac tissue engineering, further supports market growth. The presence of leading biotechnology companies and renowned research institutions also plays a crucial role in propelling advancements in this field. Thus, the combined with favourable regulatory environments and increasing investments in healthcare, these factors are positioning North America as the dominant region in the global cardiac tissue engineering market.
There are five main regional categories in the cardiac tissue engineering market: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Due to the high prevalence of cardiovascular disorders and the notable increase in healthcare spending, the North American region holds the highest share of the market for cardiac tissue engineering in 2023. The adoption and advancement of novel cardiac treatments are aided by the strong healthcare system and significant financing for medical research and development. Furthermore, the aging population in the area raises the incidence of cardiovascular diseases, which increases the need for cutting-edge therapeutic approaches. The industry is also supported by North America’s strong emphasis on technological innovation and early adoption of cutting-edge medical technologies, such as cardiac tissue engineering. Leading biotechnology businesses and prestigious research institutions are also essential to the rapid progress of this discipline. Thus, these elements—along with more investments in healthcare and favourable regulatory frameworks—are establishing North America as the predominant region in the worldwide cardiac tissue engineering market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=264276500
Key Market Players
The cardiac tissue engineering market is dominated by several major players, including Terumo Corporation (Japan), Artivion, Inc. (US), Baxter International, Inc. (US), Teijin Limited (Japan), Medtronic Plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Elutia (US), W. L. Gore & Associates, Inc. (US), Meril Lifesciences Pvt. Ltd. (India), Fujifilm Holdings Corporation (Japan), Vascudyne, Inc. (US), BICO – THE BIO CONVERGENCE COMPANY (Sweden), ReproCELL, Inc. (US), PromoCell GmbH (Germany), Axol Bioscience Ltd. (UK), BPS Bioscience, Inc. (US), Cell Application, Inc. (US), and Viscofan DE GmbH (Germany).
Terumo Corporation (Japan)
Terumo Corporation is a leading player in the cardiac tissue engineering market, recognized for its HeartSheet product derived from autologous skeletal myoblast sheets. This product is designed to treat heart failure caused by chronic ischemic disease and has gained approval under Japan’s expedited regulatory framework for regenerative medicine. Terumo’s extensive global reach, spanning over 160 countries, and its comprehensive cardiovascular division enhance its position in the industry. The company’s focus on innovative product development and global distribution underlines its leadership and capability in addressing diverse cardiac care needs.
Artivion, Inc. (US)
Artivion, Inc., previously known as CryoLife Inc., is a notable player in the cardiac tissue engineering sector, particularly recognized for its SynerGraft product. This product helps to reduce immune rejection risk while supporting natural tissue regeneration. Artivion’s strategic presence across multiple regions, including North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America, ensures broad accessibility to its advanced medical devices and implantable human tissues. This extensive reach supports global adoption and reinforces Artivion’s role in advancing cardiac care solutions.
Baxter International, Inc. (US)
Baxter International Inc. stands out in the cardiac tissue engineering market for its innovative contributions to medical technology and regenerative therapies. The company’s advanced surgery segment offers Peri-Guard and Supple Peri-Guard products for cardiothoracic surgery, made from bovine pericardium. These products are noted for their exceptionally low adverse event rate of less than 0.07%. Baxter’s extensive global network, including the US, Europe, the Middle East, Africa, Latin America, Asia, Canada, Japan, Australia, and New Zealand, ensures wide availability of its high-quality cardiac solutions, reinforcing its significant role in the market.
For more information, inquire now! Inquire Now
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cardiac-tissue-engineering-market-264276500.html